

P082 Important barriers and facilitators for involving patients in guideline development and implementation for genitourinary cancers

EUR Urol Suppl 2019;18(11):e3509

Bjorkqvist J.E.¹, MacLennan S.¹, Giles R.H.², Cornford P.³, MacLennan S.J.¹

¹University of Aberdeen, Dept. of Academic Urology, Aberdeen, United Kingdom, ²International Kidney Cancer Coalition, Dept. of Urology, Duivendrecht, The Netherlands, ³Royal Liverpool University Hospitals Trust, Dept. of Urology, Liverpool, United Kingdom

Introduction & Objectives: The importance of patient involvement in the development of clinical practice guidelines is internationally recognised. Integrating patient preferences and values within guidelines can lead to improved quality of care. However, studies have shown that there is a lack of adherence to these recommendations. European Association of Urology (EAU) guidelines have international reach, robust guideline development processes, an established patient information section and existing links to European cancer patient organisations, making the EAU and genitourinary cancers an ideal proving ground to develop and test an integrated model of patient involvement in guideline development. The aim of the EVOLVE study is to explore barriers and facilitators for patient involvement and to develop a model of meaningful patient involvement to address which stakeholders to involve, how to involve them and at what stage of the guideline development.

Materials & Methods: A systematic review was carried out to evaluate the published models of patient involvement in the development and implementation of guidelines and to identify barriers and facilitators for patient involvement in guideline development. Semi-structured interviews were carried out with members of five EAU guideline panels, including clinicians and patient representatives, to determine further barriers and facilitators specific to patient involvement in guideline development and implementation for genitourinary cancers in Europe.

Results: Eight distinct models of patient involvement in guideline development were identified in the systematic review. Two models showed higher levels of evidence of patient satisfaction with involvement, elicited patient views in guidelines and improved person-centred care. Key recommendations for patient involvement in guideline development identified via the systematic review and semi-structured interviews with EAU guideline panel members include:

- Training and support for patient representatives;
- Clear expectations and role descriptions for patient representatives;
- Access to wider European patient networks and methods for soliciting patient views.

Conclusions: The EVOLVE study is a unique collaboration of a professional society (EAU), guideline panels, researchers, clinicians and patient representatives to improve guideline development and implementation for genitourinary cancers. The results of the systematic review and semi-structured interviews with key stakeholders will inform the design of the final integrated model of patient involvement in guidelines. Through understanding current models and barriers and facilitators for patient involvement in guideline development we may improve practice and work towards improved guideline adherence, shared-decision making and patient-centered care.